TipRanks
Xuanzhu Biopharmaceutical Co., Ltd. Class H (HK:2575)
:2575
Hong Kong Market
2575
Xuanzhu Biopharmaceutical Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:2575 full AI Analyst Report?

Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Stock News & Sentiment

2 Followers
Xuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks
Premium
Company Announcements
Xuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks
24d ago
2575
Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review
Premium
Company Announcements
Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review
25d ago
2575
Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib
Premium
Company Announcements
Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib
1M ago
2575
Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
Premium
Company Announcements
Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
2M ago
2575
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
Premium
Company Announcements
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
2M ago
2575
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
Premium
Company Announcements
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
3M ago
2575
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
Premium
Company Announcements
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
3M ago
2575
More HK:2575 News >

2575 News on the Web

Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
TipRanks News
Bullish
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
TipRanks News
Neutral
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
TipRanks News
Bullish
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
TipRanks News
Bearish
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
TipRanks News
Neutral
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
TipRanks News
Bullish
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
TipRanks News
Neutral
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.75 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is HK:2575’s Media Buzz Sentiment?
Currently, no data Available
What is HK:2575’s weekly average amount of articles?
In an average week, 0.75 articles about HK:2575 are published.
    What is HK:2575’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    AMGNAmgen
    GKOSGlaukos
    OVIDOvid Therapeutics
    ABTAbbott Laboratories
    IQVIQVIA Holdings
    Showing the stocks with the most bullish news sentiment over the past week